Company: SHPH
Filing Date: 2025-02-13
Form Type: S-1
Source: 0001493152-25-006202
Chunk: 186

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-13
Form: S-1
Chunk 186
---
. In relation to the settlements described above, the Company recognized a loss on settlement of convertible debt of $ 762,186and $ 833,501for the three and nine months ended September 30, 2024.

During the three and nine months ended September 30, 2023, the Company recorded interest expense of $ 623,465and $ 1,952,147respectively, which included amortization of debt discount as interest expense of $ 538,302and $ 1,550,479respectively. During the three and nine months ended September 30, 2023, the Company settled $ 331,800and $ 1,925,700of principal, respectively, and settled $ 54,096and $ 294,927, respectively, of accrued interest, which settlements were made in the form of 62,761and 297,625shares of common stock, respectively, during the three and nine months ended September 30, 2023.

As of September 30, 2024, the outstanding principal, debt discount and net carry value for the convertible note was $ 0.

| F-15 |

Note 6 – Stockholders’ Equity

Common Stock

During the three and nine months ended September 30, 2024, the Company issued:

| ● | 719,148                                                                                                                                  
 and 797,345 shares of common stock to settle $1,172,850 and $1,408,050 of principal and $35,888 and $54,670 of interest on a convertible 
 note and incurred $762,186 and $833,501 of loss on settlement, respectively.                                                             |
| ● | 5,002                                                                                                                                    
 and 24,349 shares of common stock issued for vesting of restricted stock units, respectively.                                            |
| ● | 115,716                                                                                                                                  
 shares of common stock issued for the round up of reverse split fractional shares.                                                       |

During the three and nine months ended September 30, 2023, the Company issued:

| ● | 62,761                                                                                                                                
 and 297,625 shares of common stock to settle $331,800 and $1,925,700 of principal and $54,096 and $294,927 of interest, respectively, 
 on a Convertible Note and incurred $43,414 and $477,221 of loss on settlement, respectively.                                          |
| ● | 1,876                                                                                                                                 
 and 1,876 shares of common stock issued for